PB1771 EFFECTS OF AJWA ON DISEASE COMPLICATIONS AND CARDIAC AMONG HEMATOLOGICAL MALIGNANCY AND AJWA NANOFORMULATIONS ON THE ANTI‐CANCER AND SAFETY

Background: Phoenix dactylifera, (Ajwa) has been known for a long time for its nutritive and medicinal properties. Aims: To evaluate the benefit of Ajwa in minimizing disease complications and cardiac on Pediatric Hematological malignancy at King Abdulaziz University Hospital, Jeddah, Saudi Arabia and to preclinically evaluate Nanoformulated Ajwa Bioactive compounds (N‐Ajwa) on Anti‐cancer efficacy and prevention of cardiac toxicity‐mediated by Doxorubicin (DOX). Methods: Our investigation include clinical and preclinical studies. The clinical study is a controlled trial of pediatric cancer patients between 2008 and 2018. A total of 200 patients were screened. Out of the 200 patients, 56 patients were included, 10 patients were AML (17.8%). Out of those 56, 26 (46.43%) agreed to take Ajwa and 30 served as control (53.57%). Both groups were assessed based on the following parameters: infection rates, frequency of hospital admissions for fever neutropenia, safety and mortality rate. The preclinical study examined the impact of N‐Ajwa on the anti‐cancer efficacy and cardiac safety of DOX in human breast cancer in female nude mice model. Results: Out of the 56 patients included, twenty six patients opted to be on Ajwa and the rest served as control. The supplementation of Ajwa significantly reduced hospital admissions and infections ( P  = 0.009 and P  < 0.001 respectively). Ajwa group had a better survival rate in comparison to those in the non‐Ajwa group (stratified log‐rank P  = 0.005), where the main cause of death of patients on the non‐Ajwa group was disease progression associated with infections (77%), cardiac problems were documented in 3 AML patients(30%). Those who were compliant on Ajwa showed recovery of cardiac problems. Ajwa showed some sort of cardiac protection in cardiac patients. N‐Ajwa bioactive ingredients protected against cardiac toxicity without any impact on anti‐cancer effects of DOX. Summary/Conclusion: This controlled study showed the regular intake of Ajwa is safe and significantly decreases disease complications including cardiac and infection and improved survival. Additionally, Ajwa have an effective role in cardiac protection against Doxorubicin.